Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
2006

Reverting ER-Negative Breast Cancer to ER-Positive with Trastuzumab

Sample size: 10 publication Evidence: low

Author Information

Author(s): Munzone Elisabetta, Curigliano Giuseppe, Rocca Andrea, Bonizzi Giuseppina, Renne Giuseppe, Goldhirsch Aron, Nolè Franco

Primary Institution: European Institute of Oncology

Hypothesis

Can trastuzumab treatment revert ER-negative breast cancer to an ER-positive phenotype?

Conclusion

Some ER-negative tumors may revert to an ER-positive phenotype after treatment with trastuzumab, increasing treatment options.

Supporting Evidence

  • Three out of 10 patients showed reversion to ER-positive phenotype after treatment.
  • One patient received letrozole for 3 years without evidence of progression after reversion.
  • The study suggests that ER-negative phenotype may not be permanent.

Takeaway

This study shows that some breast cancer patients who initially have tumors without estrogen receptors can develop those receptors after treatment, which might help them respond better to certain therapies.

Methodology

Ten patients with advanced HER-2 overexpressing breast cancer were treated with trastuzumab and chemotherapy, and their tumors were reassessed for ER expression.

Limitations

The small sample size and variable timing of reassessment limit the conclusions that can be drawn.

Participant Demographics

All participants had advanced breast cancer with HER-2 overexpression and were initially ER-negative.

Digital Object Identifier (DOI)

10.1186/bcr1366

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication